PMID- 22594305
OWN - NLM
STAT- MEDLINE
DCOM- 20130322
LR  - 20151119
IS  - 1502-7708 (Electronic)
IS  - 0036-5521 (Linking)
VI  - 47
IP  - 8-9
DP  - 2012 Sep
TI  - Esophageal motor dysfunction plays a key role in GERD with globus 
      sensation--analysis of factors promoting resistance to PPI therapy.
PG  - 893-9
LID - 10.3109/00365521.2012.685756 [doi]
AB  - OBJECTIVE: Patients with gastroesophageal reflux disease (GERD) also have various 
      extra-esophageal symptoms. Laryngopharyngeal reflux disease (LPRD) is a subtype 
      of GERD associated with globus sensation, but proton pump inhibitor (PPI) therapy 
      achieves disappointing results. This study investigated esophageal motility in 
      GERD patients with globus sensation who were resistant to PPI therapy. DESIGN: 
      The subjects were 350 patients with globus sensation. All patients underwent both 
      laryngoscopy and upper gastrointestinal endoscopy to exclude organic disease. 
      After 4 weeks of treatment with rabeprazole sodium (20 mg daily), the patients 
      were divided into PPI-responsive and PPI-resistant groups. Then we investigated 
      esophageal motility in the PPI-resistant group by a multichannel intraluminal 
      impedance and manometry study. RESULTS: A total of 119 patients (55.6%) were 
      resistant to PPI therapy, among whom 57 patients (47.9%) had abnormal esophageal 
      motility. They included 36 patients (66.4%) with ineffective esophageal motility, 
      9 patients (14.4%) with achalasia, 6 patients (9.6%) with diffuse esophageal 
      spasm, 5 patients (8%) with nutcracker esophagus, and 1 patient (1.6%) with 
      hypertensive lower esophageal sphincter. There were significant differences of 
      upper esophageal sphincter pressure and esophageal body peristalsis between the 
      patients with PPI-resistant LPRD and healthy controls matched for age and sex. 
      CONCLUSION: Among patients with PPI-resistant LPRD, 47.9% had abnormal esophageal 
      motility.
FAU - Tsutsui, Hideaki
AU  - Tsutsui H
AD  - Department of Internal Medicine, Division of Gastroenterology, Kawasaki Medical 
      School, Kurashiki, Japan.
FAU - Manabe, Noriaki
AU  - Manabe N
FAU - Uno, Masako
AU  - Uno M
FAU - Imamura, Hiroshi
AU  - Imamura H
FAU - Kamada, Tomoari
AU  - Kamada T
FAU - Kusunoki, Hiroaki
AU  - Kusunoki H
FAU - Shiotani, Akiko
AU  - Shiotani A
FAU - Hata, Jiro
AU  - Hata J
FAU - Harada, Tamotsu
AU  - Harada T
FAU - Haruma, Ken
AU  - Haruma K
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
DEP - 20120518
PL  - England
TA  - Scand J Gastroenterol
JT  - Scandinavian journal of gastroenterology
JID - 0060105
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Chi-Square Distribution
MH  - *Drug Resistance
MH  - Electric Impedance
MH  - Esophageal Motility Disorders/physiopathology
MH  - Esophageal Sphincter, Upper/physiopathology
MH  - Esophagus/*physiopathology
MH  - Female
MH  - Humans
MH  - Laryngopharyngeal Reflux/complications/*drug therapy/*physiopathology
MH  - Male
MH  - Manometry
MH  - Middle Aged
MH  - Peristalsis
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Rabeprazole
MH  - Sensation
MH  - Statistics, Nonparametric
MH  - Surveys and Questionnaires
EDAT- 2012/05/19 06:00
MHDA- 2013/03/23 06:00
CRDT- 2012/05/19 06:00
PHST- 2012/05/19 06:00 [entrez]
PHST- 2012/05/19 06:00 [pubmed]
PHST- 2013/03/23 06:00 [medline]
AID - 10.3109/00365521.2012.685756 [doi]
PST - ppublish
SO  - Scand J Gastroenterol. 2012 Sep;47(8-9):893-9. doi: 10.3109/00365521.2012.685756. 
      Epub 2012 May 18.